4502 and TAK Related Headlines
Go Back- FDA approves Takeda's Mimrylo for rare blood cancer polycythemia vera
- Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
- ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
- FDA approves Takeda's Orzeyful for narcolepsy type 1 in adults
- U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
- Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track
- Takeda psoriasis drug shows skin clearance in Phase 3 trials
- Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
- Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products
- Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
- New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
- Takeda's zasocitinib beats deucravacitinib in psoriasis study
- Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
- U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
- Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
- Takeda reports positive Phase 2/3 trial results for TAK-881 in immune disorder
- Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
- Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
- Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
- Takeda reports positive pediatric trial results for ENTYVIO ulcerative colitis treatment
- Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
- U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
- Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
- Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content¹
- Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics
- Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
- Takeda reports positive phase 3 results for zasocitinib psoriasis drug
- Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
- Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
- Innovent Biologics closes $11.4 billion partnership with Takeda
- Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies
- Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
- Takeda reports 7-year dengue vaccine data showing sustained protection
- New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
- Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filin
- HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
- Innovent Biologics partners with Takeda in $11.4 billion cancer drug deal
- Takeda partners with Innovent for $1.2 billion oncology deal
- Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
- Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market
4502 and TAK Related Press Releases
Go Back- Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
- ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
- U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
- Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track
- Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
- Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products
- Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
- New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
- Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
- U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
- Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
- Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
- Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
- Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
- Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
- U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
- Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
- Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content¹
- Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics
- Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
- Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
- Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
- Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies
- Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
- New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
- Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filin
- HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
- Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
- Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market
4502 and TAK Related SEC Filings
Go Back- Form 4 TAKEDA PHARMACEUTICAL For: Aug 19 Filed by: Plump Andrew Stewart
- Form 4 TAKEDA PHARMACEUTICAL For: Aug 18 Filed by: Greenway Nicola Deidre Petal
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Plump Andrew Stewart
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Greenway Nicola Deidre Petal
- Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Pacheco Rhonda Janice
- Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Ibrahim Ramy Riad Ahmed
- Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Farajallah Awny Samaan Botros
- Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Plump Andrew Stewart
- Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Duprey Lauren Rusckowski
- Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Pignagnoli Agosti Marcello
- Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Bitetti Teresa Marie
- Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Shannon Elaine Mary
- Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Ricci Gabriele
- Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Greenway Nicola Deidre Petal
- Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Kim Julie So-Young
- Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Platford Giles Richard
- Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Furney Natalie Anne Marie
- Form 4 TAKEDA PHARMACEUTICAL For: Aug 11 Filed by: Shannon Elaine Mary
- Form 4 TAKEDA PHARMACEUTICAL For: Aug 10 Filed by: Greenway Nicola Deidre Petal
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Shannon Elaine Mary
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Greenway Nicola Deidre Petal
- Form 6-K TAKEDA PHARMACEUTICAL For: Aug 05
- Form 6-K TAKEDA PHARMACEUTICAL For: Jul 30
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Pignagnoli Agosti Marcello
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Platford Giles Richard
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Duprey Lauren Rusckowski
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Ricci Gabriele
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Furney Natalie Anne Marie
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Shannon Elaine Mary
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Greenway Nicola Deidre Petal
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Pacheco Rhonda Janice
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Farajallah Awny Samaan Botros
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Ibrahim Ramy Riad Ahmed
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Bitetti Teresa Marie
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Plump Andrew Stewart
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Kim Julie So-Young
- Form 6-K TAKEDA PHARMACEUTICAL For: Jul 09
- Form 6-K TAKEDA PHARMACEUTICAL For: Jul 08
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: MARAGANORE JOHN
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: GILLIS STEVEN
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Reed Kimberly A.
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Iijima Masami
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: BROUSSARD BRUCE D
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Kimura Koichiro
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Stoffels Paulus
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Miyabashira Asuka
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Tsusaka Miki
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Furuta Milano
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Smoter Jennifer Marie
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Platford Giles Richard
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Ibrahim Ramy Riad Ahmed
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Farajallah Awny Samaan Botros
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Greenway Nicola Deidre Petal
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Pignagnoli Agosti Marcello
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Pacheco Rhonda Janice
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Furney Natalie Anne Marie
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Shannon Elaine Mary
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Ricci Gabriele
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Bitetti Teresa Marie
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Duprey Lauren Rusckowski
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Kim Julie So-Young
- Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Plump Andrew Stewart
- Form 3 TAKEDA PHARMACEUTICAL For: Jun 24 Filed by: Stoffels Paulus
- Form 3 TAKEDA PHARMACEUTICAL For: Jun 24 Filed by: BROUSSARD BRUCE D
- Form 3 TAKEDA PHARMACEUTICAL For: Jun 24 Filed by: Kimura Koichiro
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 29
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 26
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 24
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 24
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 24
- Form IRANNOTICE TAKEDA PHARMACEUTICAL
- Form 20-F TAKEDA PHARMACEUTICAL For: Mar 31
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 09
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 05
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 05
- Form 6-K TAKEDA PHARMACEUTICAL For: Jun 01
- Form 6-K TAKEDA PHARMACEUTICAL For: May 26
- Form 6-K TAKEDA PHARMACEUTICAL For: May 26
- Form 6-K TAKEDA PHARMACEUTICAL For: May 26
- Form 6-K TAKEDA PHARMACEUTICAL For: May 26
- Form 6-K TAKEDA PHARMACEUTICAL For: May 26
- Form SD TAKEDA PHARMACEUTICAL
- Form 6-K TAKEDA PHARMACEUTICAL For: May 19
- Form 6-K TAKEDA PHARMACEUTICAL For: May 13
- Form 6-K TAKEDA PHARMACEUTICAL For: May 13
- Form 3 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Smoter Jennifer Marie
- Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Platford Giles Richard
- Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Furuta Milano
- Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Kim Julie So-Young
- Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Bitetti Teresa Marie
- Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Ricci Gabriele
- Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Duprey Lauren Rusckowski
- Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Pignagnoli Agosti Marcello
- Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Plump Andrew Stewart
- Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Weber Christophe Pierre
- Form 3 TAKEDA PHARMACEUTICAL For: Apr 01 Filed by: Greenway Nicola Deidre Petal
- Form 3 TAKEDA PHARMACEUTICAL For: Apr 01 Filed by: Farajallah Awny Samaan Botros
- Form 3 TAKEDA PHARMACEUTICAL For: Apr 01 Filed by: Ibrahim Ramy Riad Ahmed
- Form 6-K TAKEDA PHARMACEUTICAL For: Mar 30
- Form 6-K TAKEDA PHARMACEUTICAL For: Mar 26
- Form 6-K TAKEDA PHARMACEUTICAL For: Mar 25
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Kim Julie So-Young
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Bitetti Teresa Marie
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Furney Natalie Anne Marie
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Higashi Emiko
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: FUJIMORI YOSHIAKI
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Pignagnoli Agosti Marcello
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Miyabashira Asuka
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Ricci Gabriele
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Orsinger Michel Bruno
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Pacheco Rhonda Janice
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Reed Kimberly A.
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Shannon Elaine Mary
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: BUTEL JEAN LUC
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Tsusaka Miki
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Weber Christophe Pierre
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Furuta Milano
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Platford Giles Richard
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: MARAGANORE JOHN
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: GILLIS STEVEN
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: CLARK IAN T
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Plump Andrew Stewart
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Hatsukawa Koji
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Iijima Masami
- Form 3 TAKEDA PHARMACEUTICAL For: Mar 18 Filed by: Duprey Lauren Rusckowski
- Form 6-K TAKEDA PHARMACEUTICAL For: Mar 02
- Form 6-K TAKEDA PHARMACEUTICAL For: Feb 10
- Form 6-K TAKEDA PHARMACEUTICAL For: Jan 29
- Form 6-K TAKEDA PHARMACEUTICAL For: Dec 18
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Duprey Lauren Rusckowski
- Form 6-K TAKEDA PHARMACEUTICAL For: Dec 08
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Bitetti Teresa Marie
- Form 144 TAKEDA PHARMACEUTICAL Filed by: Platford Giles Richard
- Form 6-K TAKEDA PHARMACEUTICAL For: Nov 28
- Form 13F-HR TAKEDA PHARMACEUTICAL For: Sep 30
- Form 6-K TAKEDA PHARMACEUTICAL For: Oct 30
- Form 6-K TAKEDA PHARMACEUTICAL For: Oct 30
- Form 6-K TAKEDA PHARMACEUTICAL For: Oct 30
- Form 6-K TAKEDA PHARMACEUTICAL For: Oct 01
